Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment

Contributors CG Au-Yeung, A Anema, JSG Montaner, RS Hogg, and EJ Mills designed the study. CG Au-Yeung, S Kanters, E Ding, and P Glaziou performed the analyses. CG Au-Yeung prepared the first draft of the manuscript. EJ Mills supervised the study. All authors revised the manuscript critically for important intellectual content. All authors approved the final version for publication. Disclosure RS Hogg has held grant funding from the National Institutes of Health, Canadian Institutes of Health Research National Health Research Development Program, and Health Canada. He has also received funding from Agouron Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals Inc., Bristol- Myers Squibb, GlaxoSmithKline, and Merck Frosst Laboratories for participating in continued medical education programs. JSG Montaner has received grants from, served as an ad hoc advisor to, or spoken at various events sponsored by Abbott, Argos Therapeutics, Bioject Inc., Boehringer Ingelheim, BMS, Gilead Sciences, GlaxoSmithKline, Hoffmann-La Roche, Janssen-Ortho, Merck Frosst, Pfizer, Schering, Serono Inc., TheraTechnologies, Tibotec, and Trimeris. He has also held grant funding from the Canadian Institutes of Health Research and National Institutes of Health. He has also received funding for research and continuing medical education programs from a number of pharmaceutical companies including Abbott, Boehringer Ingelheim, and GlaxoSmithKline. EJ Mills is supported by a Canada Research Chair in Global Health from Canadian Institutes of Health Research and unrestricted research support from Pfizer Canada Inc.